These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8821523)
1. Pharmacokinetics and stability of caldiamide sodium in rats. Okazaki O; Kurata T; Yoshioka N; Hakusui H Arzneimittelforschung; 1996 Jan; 46(1):79-83. PubMed ID: 8821523 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456 [TBL] [Abstract][Full Text] [Related]
3. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Normann PT; Hals PA Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938 [TBL] [Abstract][Full Text] [Related]
4. Quantification of dechelation of gadopentetate dimeglumine in rats. Kasokat T; Urich K Arzneimittelforschung; 1992 Jun; 42(6):869-76. PubMed ID: 1418049 [TBL] [Abstract][Full Text] [Related]
5. Placental transfer and milk secretion of gadodiamide injection in rats. Okazaki O; Murayama N; Masubuchi N; Nomura H; Hakusui H Arzneimittelforschung; 1996 Jan; 46(1):83-6. PubMed ID: 8821524 [TBL] [Abstract][Full Text] [Related]
6. The role of equilibrium and kinetic properties in the dissociation of Gd[DTPA-bis(methylamide)] (Omniscan) at near to physiological conditions. Baranyai Z; Brücher E; Uggeri F; Maiocchi A; Tóth I; Andrási M; Gáspár A; Zékány L; Aime S Chemistry; 2015 Mar; 21(12):4789-99. PubMed ID: 25678406 [TBL] [Abstract][Full Text] [Related]
7. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279 [TBL] [Abstract][Full Text] [Related]
8. Lanthanide chelates of (bis)-hydroxymethyl-substituted DTTA with potential application as contrast agents in magnetic resonance imaging. Silvério S; Torres S; Martins AF; Martins JA; André JP; Helm L; Prata MI; Santos AC; Geraldes CF Dalton Trans; 2009 Jun; (24):4656-70. PubMed ID: 19513474 [TBL] [Abstract][Full Text] [Related]
9. Elimination of gadolinium-DTPA by peritoneal dialysis. Dörsam J; Knopp MV; Schad L; Piesche S; Carl S; Oesingmann N Nephrol Dial Transplant; 1995; 10(7):1228-30. PubMed ID: 7478129 [TBL] [Abstract][Full Text] [Related]
10. Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Schuhmann-Giampieri G Arzneimittelforschung; 1993 Sep; 43(9):1020-4. PubMed ID: 8240452 [TBL] [Abstract][Full Text] [Related]
11. Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Puttagunta NR; Gibby WA; Puttagunta VL Invest Radiol; 1996 Oct; 31(10):619-24. PubMed ID: 8889650 [TBL] [Abstract][Full Text] [Related]
12. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent. Van Wagoner M; Worah D Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503 [TBL] [Abstract][Full Text] [Related]
13. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Tweedle MF; Wedeking P; Kumar K Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190 [TBL] [Abstract][Full Text] [Related]
14. The use of a binary chelate formulation: Could gadolinium based linear contrast agents be rescued by the addition of zinc selective chelates? Gibby W; Parish W; Merrill RM; Fernandez D; Anderson CR; Merchel E; Parr R Magn Reson Imaging; 2019 May; 58():76-81. PubMed ID: 30639754 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lanthanoids as X-ray contrast agents. Pietsch H; Jost G; Frenzel T; Raschke M; Walter J; Schirmer H; Hütter J; Sieber MA Eur J Radiol; 2011 Nov; 80(2):349-56. PubMed ID: 20006455 [TBL] [Abstract][Full Text] [Related]
16. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Burtea C; Laurent S; Murariu O; Rattat D; Toubeau G; Verbruggen A; Vansthertem D; Vander Elst L; Muller RN Cardiovasc Res; 2008 Apr; 78(1):148-57. PubMed ID: 18174291 [TBL] [Abstract][Full Text] [Related]
18. GdIII complexes with fast water exchange and high thermodynamic stability: potential building blocks for high-relaxivity MRI contrast agents. Laus S; Ruloff R; Tóth E; Merbach AE Chemistry; 2003 Aug; 9(15):3555-66. PubMed ID: 12898682 [TBL] [Abstract][Full Text] [Related]
19. Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. Vexler VS; Clément O; Schmitt-Willich H; Brasch RC J Magn Reson Imaging; 1994; 4(3):381-8. PubMed ID: 8061437 [TBL] [Abstract][Full Text] [Related]
20. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]